SOUTH SAN FRANCISCO, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (DNLI) today reported financial results for the fourth quarter and year ended December 31, 2024, and provided ...
Hunter syndrome (MPS II) presentations will include analysis from continued follow-up of Phase 1/2 data for tividenofusp alfa (DNL310), currently under FDA Priority Review Preliminary data from Phase ...
当前正在显示可能无法访问的结果。
隐藏无法访问的结果